Last reviewed · How we verify

Ventricular Fibrillation — Treatment Landscape & Competitive Intelligence

Ventricular Fibrillation (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ventricular Fibrillation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Onoact LANDIOLOL Aop Hlth Us landiolol Beta-1 adrenergic receptor 2024-01-01
Bretylium Tosylate BRETYLIUM Pfizer bretylium Beta-1 adrenergic receptor 1986-01-01
Cordarone AMIODARONE Pfizer Antiarrhythmic sodium channels, potassium channels, calcium channels 1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Ventricular Fibrillation
  2. Aop Hlth Us · 1 drug in Ventricular Fibrillation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ventricular Fibrillation:

Cite this brief

Drug Landscape (2026). Ventricular Fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ventricular-fibrillation. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing